<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865122</url>
  </required_header>
  <id_info>
    <org_study_id>GIFT-02</org_study_id>
    <nct_id>NCT02865122</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in Infant With SBS</brief_title>
  <acronym>GIFT</acronym>
  <official_title>A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elgan Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elgan Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620&#xD;
      compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old)&#xD;
      with SBS following surgical resection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision based on enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in %PN/IV</measure>
    <time_frame>baseline and end of treatment or 24 weeks, whichever occurs first</time_frame>
    <description>Percent change in %PN/IV from baseline based on caloric intake</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>NTRA-9620-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTRA-9620-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo To be dosed orally for 24 weeks, 4 times/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTRA-9620</intervention_name>
    <description>Oral daily dose</description>
    <arm_group_label>NTRA-9620-A</arm_group_label>
    <arm_group_label>NTRA-9620-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral daily dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Subject must be at least 28 weeks post-menstrual age and up to 52 weeks chronological&#xD;
             age at enrollment.&#xD;
&#xD;
          2. Subject weight must be at least 500 grams (17.6 ounces) at time of enrollment.&#xD;
&#xD;
          3. After major surgical resection leading to SBS, the subject has maximally 70% of&#xD;
             expected bowel length preserved or an ostomy in place such that ≤ 70% of the small&#xD;
             bowel is available for nutrient absorption.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subject has undergone any bowel lengthening procedure.&#xD;
&#xD;
          2. Subject has a malabsorption disorder due to:&#xD;
&#xD;
               -  congenital etiology (such as microvilli inclusion disease, tufting enteropathy)&#xD;
&#xD;
               -  Untreated Hirchsprung's disease&#xD;
&#xD;
          3. Uncontrolled systemic infection, acute gastroenteritis, pneumonia, cardiovascular or&#xD;
             other abnormality including EKG findings that in the opinion of the investigator makes&#xD;
             the infant unstable and at significant risk of not completing first 12 weeks of the&#xD;
             study.&#xD;
&#xD;
          4. Subjects with hyperinsulinemia.&#xD;
&#xD;
          5. Subjects with unexplained or recurrent hypoglycemia with blood glucose ≤ 50 mg/dL&#xD;
             within 48 hours of treatment initiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>52 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02865122/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NTRA-9620-A</title>
          <description>NTRA-9620 Dose 1: 2 IU/kg To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="P2">
          <title>NTRA-9620-B</title>
          <description>NTRA-9620 Dose 2 - 1 IU/kg To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo To be dosed orally for 24 weeks, 4 times/day&#xD;
Placebo: Oral daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No subjects randomized to placebo. Study was terminated early.</population>
      <group_list>
        <group group_id="B1">
          <title>NTRA-9620-A</title>
          <description>NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="B2">
          <title>NTRA-9620-B</title>
          <description>NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo To be dosed orally for 24 weeks, 4 times/day&#xD;
Placebo: Oral daily dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in %PN/IV</title>
        <description>Percent change in %PN/IV from baseline based on caloric intake</description>
        <time_frame>baseline and end of treatment or 24 weeks, whichever occurs first</time_frame>
        <population>During the course of the study only two (2) subjects were enrolled prior to discontinuation. Thus, no conclusions regarding the efficacy or safety (risk/benefit) of NTRA-9620 in the short bowel syndrome (SBS) population can be determined from this study.</population>
        <group_list>
          <group group_id="O1">
            <title>NTRA-9620-A</title>
            <description>NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
          </group>
          <group group_id="O2">
            <title>NTRA-9620-B</title>
            <description>NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo To be dosed orally for 24 weeks, 4 times/day&#xD;
Placebo: Oral daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in %PN/IV</title>
          <description>Percent change in %PN/IV from baseline based on caloric intake</description>
          <population>During the course of the study only two (2) subjects were enrolled prior to discontinuation. Thus, no conclusions regarding the efficacy or safety (risk/benefit) of NTRA-9620 in the short bowel syndrome (SBS) population can be determined from this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Only one patient experienced Serious Adverse Events. There were no deaths in the study. There were no &quot;Other&quot; Adverse Events experienced in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>NTRA-9620-A</title>
          <description>NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="E2">
          <title>NTRA-9620-B</title>
          <description>NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day&#xD;
NTRA-9620: Oral daily dose</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo To be dosed orally for 24 weeks, 4 times/day&#xD;
Placebo: Oral daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <description>Aspiration Neonatal respiratory distress system Pulmonary hypertension Pulmonary vein stenosis</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miki Olshansky, Chief Executive Officer</name_or_title>
      <organization>Elgan Pharma Ltd.</organization>
      <phone>972-4-6098600</phone>
      <email>Miki@elganpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

